Addex raises CHF40M via capital offering
Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds
Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall
Global M&A By the Numbers: Q1 2022
Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes
Geneva-based Addex Therapeutics Ltd. completed a CHF40 million capital offering.
The company issued 13,037,577 new shares at CHF3.13 apiece.
Addex intends to use the proceeds to develop its portfolio of drug candidates, including registration studies for lead program dipraglurant, a treatment for Parkinson's disease.